MOUNTAIN VIEW, Calif.,
March 17, 2015 /PRNewswire/
-- Omnicell, Inc. (Nasdaq: OMCL), a leading provider of
medication and supply management solutions to healthcare systems,
today announced that it is delaying the filing of its Annual Report
on Form 10-K for the year ended December 31,
2014 (the "Form 10-K").
On February 27, 2015, Omnicell
received a notice from an Omnicell employee alleging, among other
matters, the existence of a "side letter" arrangement with an
Omnicell customer for certain discounts and Omnicell products that
were to be provided at no cost, but which were not reflected in the
final invoices paid by the customer. Following the receipt of this
notice, Omnicell commenced an internal investigation into these
allegations.
Omnicell has determined that the internal investigation will not
be concluded in time to file the Form 10-K within the automatic
15-day extension period. Once the internal investigation process is
complete, Omnicell plans to file its Form 10-K as soon as
practicable thereafter.
Omnicell also announced today that it does not expect the
investigation to have any bearing on its competitive position in
the marketplace or customer interest in its products. During
its earnings call of February 3,
2015, the Company provided guidance for 2015 and, thus far,
is not changing that guidance. On the earnings call, Omnicell said
that it expected revenue to be between $480
million and $490 million for 2015, an increase of 9% to 11%,
Non-GAAP earnings to be between $1.35 and
$1.40 per share and product bookings to be between
$390 million and $405 million in
2015. The Company also said on the earnings call that it expected
steady revenue and earnings growth through the year, and projected
revenue for the first quarter of 2015 to be between $110 million and $115 million of revenue, with
Non-GAAP earnings per share of approximately $0.23.
On February 26, 2015, Omnicell
also announced that it had signed an agreement to acquire MACH4
Pharma Systems in Germany, subject
to closing conditions. If that acquisition closes, and assuming a
close date of April 1, 2015, the
Company stated it would expect its 2015 revenue guidance to
increase to between $492 million and $505
million, its Non-GAAP earnings guidance to be between
$1.31 to $1.36 per share, and its
product bookings to be between $398 million
and $416 million.
During a conference call to be held on Wednesday, March 18, 2015, at 5:30 a.m. PDT Omnicell's Chief Executive Officer
and Chief Financial Officer will discuss the delay in its 10-K
filing, its reaffirmation of the guidance given on February 3, 2015 and its recent announcement of
an agreement to acquire MACH4 Systems. The conference call can be
monitored by dialing 1-800-696-5518 within the U.S. or
1-706-758-4883 for all other locations. The Conference ID # is
9454291. Internet users can access the conference call at
http://ir.omnicell.com/events.cfm. A replay of the call will be
available today at approximately 8:30 a.m.
PT and will be available until 11:59
p.m. PT on April 1,
2015. The replay access numbers are 1-855-859-2056 within the
U.S. and 1-404-537-3406 for all other locations, Conference ID # is
9454291.
About Omnicell
Since 1992, Omnicell (NASDAQ: OMCL) has been creating new
efficiencies to improve patient care, anywhere it is delivered.
Omnicell is a leading supplier of comprehensive automation and
business analytics software for patient-centric medication and
supply management across the entire healthcare continuum— from the
acute care hospital setting to post-acute skilled nursing and
long-term care facilities to the home.
More than 3,000 customers worldwide have utilized Omnicell
Automation and Analytics solutions to increase operational
efficiency, reduce errors, deliver actionable intelligence and
improve patient safety. Omnicell Medication Adherence solutions,
including its MTS Medication Technologies brand, provide innovative
medication adherence packaging solutions to help reduce costly
hospital readmissions. In addition, these solutions enable
approximately 6,000 institutional and retail pharmacies worldwide
to maintain high accuracy and quality standards in medication
dispensing and administration while optimizing productivity and
controlling costs.
For more information about Omnicell, Inc. please visit
www.omnicell.com.
OMCL-E
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, regarding Omnicell's timing of the filing of its Form 10-K,
financial guidance for the first quarter and full year of 2015 and
its pending acquisition of Mach4 Systems. To the extent any
statements contained in this release deal with information that is
not historical, these statements are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. As such, they are subject to the occurrence of many events
outside Omnicell's control and are subject to various risk factors
that could cause actual results to differ materially from those
expressed or implied in any forward-looking statement. Prospective
investors are cautioned not to place undue reliance on
forward-looking statements. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Omnicell undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Logo -
http://photos.prnewswire.com/prnh/20120731/SF48971LOGO-a
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/omnicell-provides-update-on-form-10-k-filing-and-reaffirms-2015-financial-guidance-300051938.html
SOURCE Omnicell, Inc.